Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2012, 5(2), 155-168; doi:10.3390/ph5020155
Review

Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation

1,*  and 1,2
Received: 26 December 2011; in revised form: 1 February 2012 / Accepted: 1 February 2012 / Published: 3 February 2012
(This article belongs to the Special Issue Anticoagulants)
View Full-Text   |   Download PDF [370 KB, uploaded 3 February 2012]
Abstract: Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients. Dabigatran is introduced into clinical practice, although many issues regarding this drug are still unclear, like laboratory monitoring, use in elderly patients, drug- and food-interactions and use in patients with renal insufficiency. Additionally, there is no antidote for dabigatran. Thus, aim of the present review is to give an overview of concerns and unresolved issues concerning dabigatran.
Keywords: atrial fibrillation; dabigatran; anticoagulation atrial fibrillation; dabigatran; anticoagulation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Stöllberger, C.; Finsterer, J. Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation. Pharmaceuticals 2012, 5, 155-168.

AMA Style

Stöllberger C, Finsterer J. Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation. Pharmaceuticals. 2012; 5(2):155-168.

Chicago/Turabian Style

Stöllberger, Claudia; Finsterer, Josef. 2012. "Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation." Pharmaceuticals 5, no. 2: 155-168.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert